VIVUS Inc. (VVUS)

5.00
0.03 0.60
NASDAQ : Health Technology
Prev Close 4.97
Open 4.98
Day Low/High 4.83 / 5.04
52 Wk Low/High 2.15 / 9.88
Volume 55.07K
Avg Volume 167.50K
Exchange NASDAQ
Shares Outstanding 10.63M
Market Cap 56.02M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus

The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.

Vivus (VVUS) Weak On High Volume

Vivus (VVUS) Weak On High Volume

Trade-Ideas LLC identified Vivus (VVUS) as a weak on high relative volume candidate

5 Stocks With Big Insider Buying: VIVUS and More

5 Stocks With Big Insider Buying: VIVUS and More

Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.

Vivus (VVUS) Is Weak On High Volume Today

Vivus (VVUS) Is Weak On High Volume Today

Trade-Ideas LLC identified Vivus (VVUS) as a weak on high relative volume candidate

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators

European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.

November 7th Options Now Available For Vivus

November 7th Options Now Available For Vivus

Investors in Vivus, Inc. saw new options become available today, for the November 7th expiration.

Today's Perilous Reversal Stock: Vivus (VVUS)

Today's Perilous Reversal Stock: Vivus (VVUS)

Trade-Ideas LLC identified Vivus (VVUS) as a "perilous reversal" (up big yesterday but down big today) candidate

September 26th Options Now Available For Vivus (VVUS)

September 26th Options Now Available For Vivus (VVUS)

Investors in Vivus, Inc. saw new options become available today, for the September 26th expiration.

Why VIVUS (VVUS) Stock Is Up Today

Why VIVUS (VVUS) Stock Is Up Today

Shares of VIVUS (VVUS) were up in morning trading Thursday after the FDA approved the company's erectile dysfunction drug Stendra.

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.

How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval?

How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval?

Shares of Orexigen Therapeutics (OREX) were down in afternoon trading Thursday despite the FDA's approval of the company's diet pill Contrave.

Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised

Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised

Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.

Oversold Conditions For Vivus (VVUS)

Oversold Conditions For Vivus (VVUS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of March 2015 Options Trading For Vivus (VVUS)

First Week Of March 2015 Options Trading For Vivus (VVUS)

Investors in Vivus, Inc. saw new options become available this week, for the March 2015 expiration.

'Mad Money' Lightning Round: I Believe in Rite Aid

'Mad Money' Lightning Round: I Believe in Rite Aid

Cramer isn't buying Akamai Technologies, prefers Travelers over Chubb and wants General Electric to provide some answers.

Jim Cramer's 'Mad Money' Recap: High Hopes and Low-Expectation Stocks

Jim Cramer's 'Mad Money' Recap: High Hopes and Low-Expectation Stocks

Stick with companies where any good news will be met with big gains, Cramer says.

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout

By Alex Gavrish, Etalon Investment Research; author of "Wall Street Back To Basics" The main beneficiary of a recent acquisition of Idenix Pharmaceuticals Inc (NASDAQ:IDIX) by Merck & Co., I...

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel

EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel

EnteroMedics and its VBLOC "fat-zapping" implantable medical device will be the focus of an FDA advisory panel meeting next Tuesday, June 17. If FDA follows historical form, the agency's review of VBLOC's safety and efficacy will be available publicly tomorrow morning.

Top Swing Trade Ideas for Wednesday June 11: Facebook, Vivus, More

Top Swing Trade Ideas for Wednesday June 11: Facebook, Vivus, More

Facebook, Vivus and Wageworks are our big swing trades for today. So how should investors buy and sell?

FDA Delays Decision on Orexigen Obesity Pill by 3 Months

FDA Delays Decision on Orexigen Obesity Pill by 3 Months

FDA needs more time to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of heart-safety related outcomes for Contrave, Orexigen said

Orexigen: 'Goldilocks' Obesity Pill Awaits FDA Approval Decision Wednesday

Orexigen: 'Goldilocks' Obesity Pill Awaits FDA Approval Decision Wednesday

Selling weight-loss pills to fat Americans is clearly more difficult than Vivus and Arena envisioned. Orexigen will face the same challenges, but of the three companies, it has the best marketing partner in Takeda because of its metabolic drug expertise.

Interesting VVUS Call Options For June 13th

Interesting VVUS Call Options For June 13th

Investors in Vivus, Inc. saw new options become available today, for the June 13th expiration.

6 Serious Questions Regarding Potential Buyout Offer For Vivus

6 Serious Questions Regarding Potential Buyout Offer For Vivus

Shares of Vivus, Inc. (NASDAQ:VVUS) declined by nearly 4% today after performing well the last couple of days based on a regulatory filing with the Securities and Exchange Commission. The filing indic...

'Mad Money' Lightning Round: Buy, Buy, Buy Starbucks

'Mad Money' Lightning Round: Buy, Buy, Buy Starbucks

Cramer is avoiding Vivus but thinks TransCanada is terrific.

Jim Cramer's 'Mad Money' Recap: Which Food Stock Will Be Bought Next?

Jim Cramer's 'Mad Money' Recap: Which Food Stock Will Be Bought Next?

In the quest for growth, the acquisition buying frenzy is only just beginning, Cramer says.

TheStreet Quant Rating: D- (Sell)